Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Kantrowitz JT, Javitt DC.

Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Review.

2.
3.

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D.

Schizophr Bull. 2012 Sep;38(5):958-66. doi: 10.1093/schbul/sbs069. Review.

4.

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Yang CR, Svensson KA.

Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27. Review.

PMID:
18805436
5.

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Moghaddam B, Javitt D.

Neuropsychopharmacology. 2012 Jan;37(1):4-15. doi: 10.1038/npp.2011.181. Epub 2011 Sep 28. Review.

6.

Glutamate as a therapeutic target in psychiatric disorders.

Javitt DC.

Mol Psychiatry. 2004 Nov;9(11):984-97, 979. Review.

PMID:
15278097
7.

The chemical biology of clinically tolerated NMDA receptor antagonists.

Chen HS, Lipton SA.

J Neurochem. 2006 Jun;97(6):1611-26. Review.

8.

NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.

Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, Tricklebank M.

Neuropharmacology. 2012 Mar;62(3):1401-12. doi: 10.1016/j.neuropharm.2011.03.015. Epub 2011 Mar 21. Review.

PMID:
21420987
9.

Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia.

Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, Bertolino A, D'Aniello A, Usiello A.

J Psychiatr Res. 2013 Oct;47(10):1432-7. doi: 10.1016/j.jpsychires.2013.06.013. Epub 2013 Jul 6.

PMID:
23835041
10.

In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia.

Puhl MD, Mintzopoulos D, Jensen JE, Gillis TE, Konopaske GT, Kaufman MJ, Coyle JT.

Neurobiol Dis. 2015 Jan;73:269-74. doi: 10.1016/j.nbd.2014.10.009. Epub 2014 Oct 23.

11.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

12.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
13.

N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.

Domino EF, Mirzoyan D, Tsukada H.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):801-11. Review.

PMID:
15363604
14.

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Coyle JT, Tsai G.

Psychopharmacology (Berl). 2004 Jun;174(1):32-8. Epub 2003 Nov 25. Review.

PMID:
15205876
15.

D-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.

Errico F, Mothet JP, Usiello A.

J Pharm Biomed Anal. 2015 Dec 10;116:7-17. doi: 10.1016/j.jpba.2015.03.024. Epub 2015 Mar 31. Review.

PMID:
25868730
16.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
17.

Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.

Anderson G, Maes M.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:5-19. doi: 10.1016/j.pnpbp.2012.06.014. Epub 2012 Jul 16. Review.

PMID:
22800757
18.
19.

Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.

Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, Lehrfeld NP, Reep J, Parker E, Silipo G, Ahissar M, Javitt DC.

Brain. 2016 Dec;139(Pt 12):3281-3295.

PMID:
27913408
20.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

Supplemental Content

Support Center